🟠 Moderate Evidence
Every glucose molecule absorbed into the bloodstream must be converted to ATP through a single enzymatic gateway: pyruvate dehydrogenase (PDH). That enzyme requires thiamine pyrophosphate—the active form of vitamin B1—to function. When thiamine is absent, pyruvate cannot enter the mitochondria, lactate accumulates instead, and cardiac energy production collapses. For heart failure patients, this is not an academic detail. According to a cross-sectional study by Hanninen and colleagues, 33% of hospitalized heart failure patients were thiamine deficient compared with 12% of matched controls—a clinically meaningful gap with direct metabolic consequences.
Key takeaways
- Thiamine deficiency affects one-third of hospitalized heart failure patients, driven largely by loop diuretic use
- PDH-mediated glucose metabolism is the primary energy pathway for the myocardium; thiamine depletion forces a metabolic shift toward lactate production and ATP shortage
- Thiamine status is not measured routinely despite rapid depletion risk (total body stores: 25–30 mg, depleted in 2–3 weeks without replenishment)
- Loop diuretics, standard therapy for heart failure, increase renal thiamine clearance and create a measurable deficiency risk
Study at a Glance
| Source | Hanninen et al., comparative clinical cohort |
| Study type | Cross-sectional observational cohort |
| Sample size | N = 150 (100 heart failure patients, 50 controls) |
| Population | Hospitalized heart failure patients vs. matched healthy controls |
| Key finding | 33% thiamine deficiency in heart failure vs. 12% in controls |
Thiamine Deficiency Prevalence in Heart Failure
Comparison of deficiency rates between heart failure patients and matched controls
Source: Hanninen et al., comparative clinical cohort | Georgian Medical Journal News
The Metabolic Bottleneck: Why Thiamine Matters for Cardiac ATP Production
Glucose metabolism bifurcates at pyruvate. In the cytoplasm, glycolysis converts glucose to pyruvate without requiring thiamine. But pyruvate cannot cross the mitochondrial membrane as acetyl-CoA—the entry substrate for the citric acid cycle—unless PDH catalyzes that transformation. PDH’s active site contains thiamine pyrophosphate (TPP), the obligate cofactor. Without TPP, the reaction stalls.
When thiamine is deficient, pyruvate is shunted toward lactate production instead, a metabolically wasteful redirection. The citric acid cycle, starved of acetyl-CoA, cannot generate the reducing equivalents (NADH, FADH2) that power oxidative phosphorylation. ATP production drops precipitously. For the myocardium—a tissue with near-zero glycogen stores and near-total dependence on oxidative metabolism—this represents a crisis state. Lactate accumulates in blood, worsening the metabolic acidosis common in decompensated heart failure.
Loop Diuretics and the Thiamine Depletion Trap
The link between diuretic therapy and thiamine deficiency is mechanistic and well-established. Loop diuretics (furosemide, torsemide, bumetanide) are first-line agents for managing fluid overload in heart failure, yet they increase renal thiamine clearance by inhibiting tubular reabsorption. Thiamine is water-soluble with negligible tissue stores—only 25–30 mg total body—making it vulnerable to rapid depletion. Without daily dietary replenishment, this reservoir can be exhausted in 2–3 weeks.
The vicious cycle is self-reinforcing: loop diuretics deplete thiamine → thiamine deficiency impairs PDH-mediated ATP generation → myocardial contractility worsens → diuretic doses escalate → further thiamine loss accelerates. This creates a metabolic ratchet mechanism that can perpetuate deterioration even when volume status improves. Clinical updates in heart failure management have not yet systematized thiamine screening or supplementation despite this plausible mechanistic link.
Beyond Heart Failure: Thiamine Deficiency in Modern Medicine
The problem extends far beyond heart failure alone. Diabetes is independently associated with low thiamine status, driven by increased renal clearance and amplified metabolic demand (glucose metabolism is the pathway most sensitive to thiamine availability). Alcohol use disorder impairs both thiamine absorption and increases urinary excretion, placing chronic users at severe risk. Bariatric surgery reduces the absorptive surface for thiamine, creating lasting micronutrient vulnerability. High carbohydrate intake increases thiamine demand proportionally—a relevant consideration in modern Western diets.
Yet thiamine status is not included in standard clinical blood panels. Hospitals do not routinely screen for thiamine deficiency even in high-risk populations. When supplementation is prescribed, it is often empirical rather than evidence-guided. Data on thiamine screening practices remain sparse, but the clinical opportunity is substantial: a water-soluble vitamin with decades of safety data could address a metabolic bottleneck in cardiac disease, yet remains invisible in standard practice.
One-third of hospitalized heart failure patients exhibited thiamine deficiency, driven largely by loop diuretic-mediated urinary losses and total body stores of only 25–30 mg, depleted within 2–3 weeks without replenishment.
— Hanninen et al., comparative clinical cohort study
What this means
Frequently asked questions
How quickly can thiamine deficiency develop in someone on loop diuretics?
Total body thiamine stores are only 25–30 mg, and without daily replenishment, these stores can be depleted in as little as 2–3 weeks. Loop diuretics accelerate this loss by increasing renal clearance, meaning symptomatic deficiency can emerge within weeks to months of initiating therapy, particularly if dietary intake is marginal or if the patient has comorbidities (diabetes, alcohol use, malabsorption) that further reduce thiamine status.
Why is thiamine deficiency not detected on routine blood work?
Thiamine is not part of standard metabolic panels or lipid panels. Measurement requires specific laboratory request (plasma thiamine or erythrocyte transketolase activity assay), which is rarely ordered unless deficiency is suspected clinically. This creates a blind spot: patients with measurable deficiency may go undiagnosed simply because no test was performed, despite metabolic evidence of its importance.
Can thiamine supplementation improve heart failure outcomes?
Supplementation trials on ejection fraction have shown mixed results, but the biochemical rationale is robust: restoring thiamine replenishes PDH cofactor, allowing normal glucose-to-ATP metabolism to resume. The lack of robust outcome data does not refute the mechanism—it reflects a research gap. Given thiamine’s safety profile and low cost, supplementation merits clinical consideration while outcome trials are awaited.
The recognition that thiamine deficiency is prevalent in heart failure and mechanistically linked to impaired ATP production through PDH represents a convergence of biochemistry, clinical observation, and therapeutic opportunity. Loop diuretics remain essential therapy, yet their thiamine-depleting effect is seldom addressed in routine care. Integrating thiamine screening and supplementation into heart failure management protocols could address a modifiable metabolic defect with minimal risk and potentially meaningful clinical benefit. Future health policy initiatives should evaluate whether thiamine assessment belongs in guideline-directed medical therapy for heart failure and related conditions.
Source: Hanninen et al., thiamine status in heart failure patients — comparative clinical cohort
Was this article helpful?
Disclaimer. This article is health journalism intended for general information and education. It is not medical advice and is not a substitute for professional diagnosis or treatment. Always consult a qualified healthcare provider about your individual circumstances. Full disclaimer →
Related Coverage
Editorial standards. This article was produced under the GMJ News editorial process, with oversight by the GMJ Editorial Board. Our editorial process. Spotted an error? Contact the editorial team.
